European regulators have ordered a recall of all batches of Amgen’s Tavneos (avacopan) after the European Commission canceled its marketing authorization for the vasculitis treatment earlier this month. The action follows an EC decision that removed authorisation for the product, triggering national drug authority follow-through. The recall raises immediate continuity questions for treatment access in Europe for patients with the relevant vasculitis indication and spotlights the compliance, documentation, and evidence expectations that can drive sudden status changes even after initial approvals. For Amgen, the development adds to regulatory execution risk around late-stage launches and post-authorization maintenance. It also increases operational pressure on distributors, prescribers, and pharmacies supporting ongoing care. The episode underlines how quickly rare-disease portfolios can be disrupted when European Commission decisions are implemented at the member-state level.